Menu Search
Equities

Getinge AB

GTN:MUN

Getinge AB

Actions
  • Price (EUR)14.44
  • Today's Change-0.07 / -0.48%
  • Shares traded250.00
  • 1 Year change-25.21%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Getinge AB is a Sweden-based company operating within healthcare sector. The Company provides hospitals and Life Science institutions with products and solutions aimed at improving clinical outcomes and optimizing workflows. The Company’s reporting segments have the following activities: Acute Care Therapies develops solutions for life-sustaining care in acute health conditions. Life Science offers a comprehensive range of equipment, technical expertise and prevention consultation contamination in pharmaceutical production, biomedical research, production of medical equipment and in various laboratory applications. Surgical Workflows offers products and services for the effective disinfection and sterilization of instruments used in operations, operating tables and others hardware for operating rooms and advanced IT systems for efficient and secure workflows in hospitals.

  • Revenue in SEK (TTM)33.59bn
  • Net income in SEK1.69bn
  • Incorporated1990
  • Employees11.85k
  • Location
    Getinge ABLindholmspiren 7,P.O. Box 8861GOETEBORG 417 56SwedenSWE
  • Phone+46 35155500
  • Fax+46 8295532
  • Websitehttps://www.getinge.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		GETI B:STO since
announced		Transaction
value
Paragonix Technologies IncDeal completed22 Aug 202422 Aug 2024Deal completed-17.48%477.00m
Data delayed at least 15 minutes, as of Nov 22 2024 15:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.